市场调查报告书
商品编码
1245746
坐骨神经痛治疗全球市场规模、份额、行业趋势分析报告(按类型、分销渠道、药物类别(非甾体抗炎药、类固醇、抗抑郁药、其他))、区域展望和预测,2022-2028 年Global Sciatica Treatment Market Size, Share & Industry Trends Analysis Report By Type, By Distribution Channel, By Drug Class (Non-Steroidal anti-inflammatory, Steroids, Antidepressants and Others), By Regional Outlook and Forecast, 2022 - 2028 |
到 2028 年,坐骨神经痛治疗的全球市场规模预计将达到 8.104 亿美元,预测期内復合年增长率为 3.5%。
製药公司越来越重视基于微丸技术开发非甾体硬膜外注射剂。 这主要是由于缺乏硬膜外类固醇治疗坐骨神经痛的批准。 基于微粒技术,硬膜外注射可以通过将药物输送到受伤的神经来减轻疼痛和炎症。 此外,这项最先进的技术有望提高可乐定的安全性和有效性。 因此,使用微丸技术的新医药产品将在预测期内进入市场,极大地推动其扩张。
未经治疗的坐骨神经痛会导致长期的背部不适。 因此,许多政府和非政府组织已采取具体措施来提高对坐骨神经痛的认识并防止延误诊断。 此类活动将通过增加对患者状况和安全治疗的了解来促进预测期内的市场扩张。
COVID-19 影响分析
COVID-19 大流行对全球坐骨神经痛药物市场的扩张产生了负面影响。 医疗保健面临的主要挑战之一是 COVID-19 大流行。 随着美国、中国、日本、印度和德国等主要国家的长期封锁,COVID-19 大流行的爆发导致部分或所有製造设施关闭。 此外,世界上大多数工业设施都已关闭或停止运营。 这对治疗坐骨神经痛的药物生产产生了一些影响。
市场增长因素
超重或肥胖的患病率增加
肥胖和超重主要是由消耗的卡路里和消耗的卡路里之间的能量不平衡引起的。 在全球范围内,含有大量脂肪和糖分的高热量食物的摄入量不断增加,许多职业都是久坐不动的,交通方式在进化,城市化进程在推进,从那时起,缺乏运动的情况在加剧。 特别是,超重的人往往会给他们的胃带来压力。 坐骨神经痛最常见的原因之一是超重。 因此,预计坐骨神经痛的发病率会随着肥胖和超重的增加而增加。 这将鼓励扩大坐骨神经痛治疗药物的市场。
老化率增加
所有国家都必须克服重大障碍,使其社会和卫生系统做好准备,以便从这一人口变化中受益。 到 2050 年,80% 的老年人将生活在低收入和中等收入国家。 人口老龄化速度比过去快得多。 到 2020 年,60 岁以上的人口将超过 5 岁以下的人口。 从 2015 年到 2050 年,地球上 60 岁以上人口的比例预计将从 12% 增加到 22%。 骨关节炎以及背部和颈部不适是老年人的常见疾病。 随着年龄的增长,我们往往会同时出现多种症状。
市场约束
对症状的认识不足
坐骨神经痛通常被认为是一种常见的腰痛,因为它并不为人所知。 坐骨神经痛通常会自行消退,但它会永久性损伤神经。 坐骨神经痛和背痛都是在做出正确诊断之前经常被误认为的背痛形式。 混淆源于许多症状相同的事实。 然而,背痛和坐骨神经痛并不完全是一回事。
输入 Outlook
按类型划分,坐骨神经痛治疗市场分为急性坐骨神经痛、慢性坐骨神经痛等。 到 2021 年,慢性坐骨神经痛部分在坐骨神经痛治疗市场中的收入份额最大。 慢性坐骨神经痛的特点是慢性坐骨神经痛持续8週以上,通常不会自行消失。 慢性坐骨神经痛可能需要非手术或手术治疗,具体取决于根本原因。 这种市场扩张可归因于慢性坐骨神经痛病例的增加、生活方式的改变以及脊柱肿瘤和椎间盘突出病例的增加。
药物类别展望
按药物类别,坐骨神经痛药物市场分为非甾体类抗炎药、类固醇、抗抑郁药等。 到 2021 年,非甾体抗炎药 (NSAID) 细分市场将在坐骨神经痛治疗市场中占据最高的收入份额。 非甾体类抗炎药 (NSAID) 是治疗坐骨神经痛最常用的药物之一。 该项目获得批准,开拓了巨大的市场潜力。 最受欢迎的药物类别、止痛药和消炎药是最有效的药物。
分销渠道展望
根据分销渠道,坐骨神经痛治疗市场分为医院药房、零售和专业药房以及在线供应商。 2021 年,医院药房部门在坐骨神经痛治疗市场中占据了相当大的收入份额。 预计该类别将在预测期内增长。 医院治疗各种有坐骨神经痛症状的患者,使他们成为该行业的主导者。 家庭护理是一种在私人家中提供护理以帮助坐骨神经痛患者的医疗服务。
区域展望
它按地区分析了北美、欧洲、亚太地区和 LAMEA 的坐骨神经痛治疗市场。 北美地区将引领坐骨神经痛治疗市场,到 2021 年将产生最大的收入份额。 许多重要公司的存在,如 Amneal Pharmaceuticals LLC、雅培、强生,以及该地区药物製剂製造技术的改进是推动市场增长的主要因素。 在同一地区,由于坐骨神经痛的流行、人类生活方式的改变以及老年人口的增加,预计用于治疗坐骨神经痛的药物需求将会增加。
The Global Sciatica Treatment Market size is expected to reach $810.4 Million by 2028, rising at a market growth of 3.5% CAGR during the forecast period.
Sciatica is a disorder in which the sciatic nerve, a sizable nerve that travels down the back, becomes inflamed and painful. Herniated discs (bulging discs between the vertebrae) and piriformis syndrome (a muscle strain in the posterior (rear) area of the hip) are only two of the many potential causes of sciatica. In most cases, sciatica treatments relieve pain and stop future nerve damage. Sciatica may be treated in several ways, such as with physical therapy, anti-inflammatory drugs, acupuncture, and steroids.
Disease problems such as osteoarthritis, spondylolisthesis, muscular spasms, and lumbar spinal stenosis are often to blame for sciatica. All across the globe, these medical disorders are becoming far more common. Therefore, the likelihood of developing sciatica may rise if certain medical conditions are more prevalent. This will increase the utilization of expected and current therapies during the projection period.
Pharmaceutical firms are placing more and more emphasis on creating non-steroidal epidural injections based on micropellet technology. This is due mainly to the fact that no epidural steroids are licensed for sciatica treatment. The epidural injection based on micropellet technology aids in lowering pain and inflammation by enabling targeted drug delivery to the injured nerves. Moreover, this cutting-edge technology is anticipated to improve the safety and effectiveness of clonidine. Therefore, throughout the duration of the projection, new pharmaceuticals created using micropellet technology would hit the market and significantly boost its expansion.
If sciatica is not treated, it may result in lower back discomfort that lasts for a long time. Therefore, numerous governmental and non-governmental groups are starting specific efforts to raise public awareness of the illness and prevent diagnostic delays. These campaigns to increase patient knowledge of the condition and safe treatment alternatives will fuel market expansion during the projected period.
COVID-19 Impact Analysis
The COVID-19 pandemic had a detrimental effect on expanding the world market for sciatica treatments. One of the main problems facing the healthcare sector was the COVID-19 pandemic. Due to the protracted lockdown in important nations, including the United States, China, Japan, India, and Germany, the COVID-19 pandemic outbreak has resulted in the partial or total suspension of manufacturing facilities. Also, this has resulted in the majority of industrial facilities throughout the globe closing down or suspending these manufacturing operations. This has some impact on the production of drugs for sciatica as well.
Market Growth Factors
The increasing rate of overweight or obesity prevalence
Obesity and overweight are primarily caused by an imbalance in energy between calories ingested and burned. Worldwide, there has been a rise in the consumption of calorie-dense foods that are rich in fat and sugar, as well as a rise in physical inactivity due to the sedentary nature of many occupations, evolving transportation options, and escalating urbanization. Much pressure is applied when someone is overweight, especially if they like to carry their extra pounds around their midsection. One of the most typical causes of sciatica is being overweight. As a result, it is expected that the incidence of sciatica will increase along with the increased prevalence of obesity or overweight. This would encourage the market for sciatica treatments to expand.
Growing proportion of aging population
To make sure that their social and health systems are ready to benefit from this demographic transformation, all nations must overcome significant obstacles. Eighty percent of senior citizens will reside in low- and middle-income countries by 2050. The population is aging considerably more quickly than in the past. In 2020, there will be more persons over 60 than under five-year-olds. The percentage of people over 60 in the globe will increase from 12% to 22% between 2015 and 2050. Osteoarthritis, as well as back and neck discomfort, are common ailments among older people. People are more prone to many conditions at once as they age.
Market Restraining Factors
Lack of awareness regarding condition
Sciatica is often assumed to be regular back pain because not enough people know about it. Even though sciatica usually goes away on its own, it can cause permanent damage to the nerve that it affects. Sciatica and lower back pain are both types of back pain, and they are sometimes mistaken for each other before a correct diagnosis is made. The confusion comes from many of the symptoms being the same. But low back pain and sciatica are not the same things at all.
Type Outlook
Based on type, the sciatica treatment market is segmented into acute sciatica, chronic sciatica and others. The chronic sciatica segment dominated the sciatica treatment market with maximum revenue share in 2021. Chronic sciatica is characterized by chronic sciatic nerve pain that lasts longer than 8 weeks and typically does not go away on its own. Depending on the underlying reason, chronic sciatica may need nonsurgical or surgical treatment. The expansion of this market may be attributed to the rise in chronic sciatica cases, changes in lifestyle, and an increase in spinal tumor and herniated disc instances.
Drug Class Outlook
By drug class, the sciatica treatment market is fragmented into non-steroidal anti-inflammatory drugs, steroids, antidepressants and others. The non-steroidal anti-inflammatory drug (NSAIDs) segment held the highest revenue share in the sciatica treatment market in 2021. To treat sciatica, non-steroidal anti-inflammatory medicines (NSAIDs) are among the most often given drugs. The items are receiving approvals, which is opening up significant market potential. The most popular class of pharmaceuticals, pain relievers, and anti-inflammatory treatments are the most efficient drugs.
Distribution Channel Outlook
On the basis of distribution channel, the sciatica treatment market is bifurcated into hospital pharmacies, retail & specialty pharmacies and online providers. The hospital pharmacies segment covered a considerable revenue share in the sciatica treatment market in 2021. Over the projection period, the category is likely to grow. Hospitals handle a variety of patients who exhibit sciatica symptoms, making them the dominant player in this industry. Homecare is a medical service that provides care inside private residences and helps people with sciatica.
Regional Outlook
Region wise, the sciatica treatment market is analyzed across North America, Europe, Asia Pacific and LAMEA. The North America region led the sciatica treatment market by generarting maximum revenue share in 2021. The presence of many significant companies, including Amneal Pharmaceuticals LLC, Abbott, and Johnson & Johnson, as well as improvements in the region's pharmaceutical formulation manufacturing technology, are the key factors driving the growth of the market. The demand for drugs used to treat sciatica is also expected to rise in the area due to the condition's prevalence, changes in human lifestyle, and an increase in the number of older people.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sorrento Therapeutics, Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals, Inc., Aurobindo Pharma Limited, Novartis AG, and Cadila Healthcare Ltd. (Zydus Cadila)
Market Segments covered in the Report:
By Type
By Distribution Channel
By Drug Class
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures